FDMT

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: SANA KRYS BMRN INCY RYTM KYMR NUVL VKTX AXSM NBIX

| Held by: XBI VTI IWM IWN VXF IBB KOMP SCHA VTWO DFAS

Scroll to Statements

Index	RUT
Market Cap	670.18M
Enterprise Value	299.83M
Income	-160.90M
Sales	88.24M
Book/sh	8.64
Cash/sh	7.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	196
IPO	Dec 11, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	7.59
P/B	1.48
P/C	1.71
P/FCF	-
EV/EBITDA	-
EV/Sales	3.40
Quick Ratio	9.34
Current Ratio	9.34
Debt/Eq	0.05
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-2.66
EPS next Y	-4.04
EPS next Q	-1.01
EPS this Y	-66.79%
EPS next Y	0.01%
EPS next 5Y	-17.39%
EPS past 3/5Y	10.05% -2.62%
Sales past 3/5Y	200.86% 44.32%
EPS Y/Y TTM	20.87%
Sales Y/Y TTM	383560.87%
EPS Q/Q	-17.38%
Sales Q/Q	21664.29%
Earnings	May 07 AMC
EPS/Sales Surpr.	-1.45% 17.76%

Insider Own	10.32%
Insider Trans	-2.30%
Inst Own	90.74%
Inst Trans	-1.11%
ROA	-31.28%
ROE	-34.92%
ROIC	-34.46%
Gross Margin	91.02%
Oper. Margin	-203.47%
Profit Margin	-182.34%
SMA20	19.04%
SMA50	29.04%
SMA200	34.50%
Trades

Shs Outstand	52.27M
Shs Float	46.88M
Short Float	27.58%
Short Ratio	14.84
Short Interest	12.93M
52W High	14.00 -8.43%
52W Low	3.86 232.12%
Volatility	8.40% 9.13%
ATR (14)	0.87
RSI (14)	67.23
Beta	2.70
Rel Volume	0.75
Avg Volume	871.25K
Volume	650,253

Perf Week	-0.47%
Perf Month	28.07%
Perf Quarter	28.97%
Perf Half Y	75.14%
Perf YTD	70.93%
Perf Year	224.56%
Perf 3Y	-29.75%
Perf 5Y	-44.60%
Perf 10Y	-
Recom	1.22
Target Price	27.62
Prev Close	12.72
Price	12.82
Change	0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$33
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$40 → $15
Nov-21-24	Initiated	Morgan Stanley	Underweight	$8
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight	$459
Apr-15-24	Initiated	Barclays	Overweight	$45
Feb-07-24	Resumed	Goldman	Buy	$81
Oct-26-23	Initiated	RBC Capital Mkts	Outperform	$25
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$32
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform	$24
Jul-05-23	Initiated	Chardan Capital Markets	Buy	$30
Jan-30-23	Initiated	BMO Capital Markets	Outperform	$50
Nov-18-22	Initiated	H.C. Wainwright	Buy	$36
Nov-15-22	Upgrade	Goldman	Neutral → Buy	$12 → $68
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12
Jun-22-22	Initiated	Jefferies	Buy	$22
Jan-04-22	Initiated	SVB Leerink	Outperform	$30
Jan-05-21	Initiated	Goldman	Neutral	$44
Jan-05-21	Initiated	Evercore ISI	Outperform	$70

Show Previous Ratings

Jun-30-26 04:05PM	4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists (GlobeNewswire)
Jun-29-26 08:00AM	4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital (GlobeNewswire) +11.03%
08:00AM	4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD (GlobeNewswire)
Jun-12-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
May-27-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
May-15-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) -6.73% -8.58%
May-07-26 04:05PM	4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
May-04-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-17-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Mar-18-26 04:05PM	4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Mar-16-26 08:00AM	4DMT to Participate in Upcoming Investor Meetings (GlobeNewswire)
Feb-28-26 02:21AM	Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? (Insider Monkey)
Feb-19-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-13-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Feb-09-26 08:00AM	4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD (GlobeNewswire)
09:53AM	Loading…
Feb-02-26 09:53AM	Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) (Insider Monkey)
Jan-17-26 08:00AM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Jan-07-26 08:00AM	4DMT Provides Company Update and Anticipated Development Milestones for 2026 (GlobeNewswire) +8.07%
Dec-27-25 07:43AM	Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely (Insider Monkey)
Dec-17-25 07:00AM	4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease (GlobeNewswire) -20.05%
Dec-12-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Dec-08-25 08:00AM	4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-20-25 08:00AM	4DMT to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-17-25 06:00AM	4DMT Appoints Kristian Humer as Chief Financial Officer (GlobeNewswire)
Nov-14-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Nov-10-25 09:15AM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Nov-06-25 04:05PM	4DMT to Participate in Jefferies 2025 London Healthcare Conference (GlobeNewswire)
06:23AM	4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:00AM	4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years (GlobeNewswire)
11:02PM	Loading…
Oct-30-25 11:02PM	4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific (GlobeNewswire)
Oct-26-25 06:05AM	4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development (Insider Monkey)
Oct-17-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +14.53%
09:55AM	Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High? (Zacks)
Oct-14-25 08:00AM	4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Oct-13-25 08:00AM	4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation (GlobeNewswire) +8.65%
Sep-12-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Sep-11-25 12:45PM	SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag (Zacks)
Sep-05-25 03:12AM	Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec" (Insider Monkey) +9.98%
Sep-02-25 08:20PM	Lightning Round: Now is time to take a little off the table with Applovin, says Jim Cramer (CNBC TV) +5.37%
08:00AM	4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness (GlobeNewswire)
Aug-25-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +11.21%
08:00AM	4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Aug-06-25 08:00AM	4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
Jul-31-25 04:05PM	4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update (GlobeNewswire) +42.67%
Jul-28-25 07:21AM	AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 \| Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies (GlobeNewswire)
Jul-24-25 08:00AM	4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists (GlobeNewswire)
Jul-21-25 08:00AM	BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer (Business Wire)
Jul-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Jul-02-25 04:05PM	4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution (GlobeNewswire)
May-28-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +7.50% +10.47%
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
May-05-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-02-25 06:51AM	FDA awards RMAT status to 4DMT diabetic macular oedema therapy (Pharmaceutical Technology) +9.30%
May-01-25 08:00AM	4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME (GlobeNewswire)
Apr-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +5.70%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -7.43%
Mar-27-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-10-25 08:00AM	4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD (GlobeNewswire)
Mar-04-25 08:05AM	4D Molecular price target lowered to $35 from $39 at RBC Capital (TipRanks)
Feb-28-25 04:05PM	4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire) -8.61%
Feb-19-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-08-25 02:30PM	4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program (GlobeNewswire)
Jan-29-25 08:00AM	4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population (GlobeNewswire) +7.53%
Jan-10-25 08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD and DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire) -5.48%
08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire)
08:00AM	4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path (GlobeNewswire)
Dec-16-24 08:00AM	4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS (GlobeNewswire)
Nov-26-24 06:51AM	4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-14-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV (GlobeNewswire)
Nov-13-24 05:20PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Sep-25-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-23-24 08:00AM	4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-19-24 02:34PM	4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate (Benzinga) -19.74%
10:30AM	4D Molecular data bode well for eye gene therapy, but shares fall (BioPharma Dive)
Sep-18-24 04:05PM	4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day (GlobeNewswire)
Sep-05-24 08:00AM	4DMT Announces Presentations at Upcoming Retina Conferences (GlobeNewswire)
Sep-03-24 08:00AM	4DMT to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-27-24 08:00AM	4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 (GlobeNewswire)
Aug-23-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-12-24 08:00AM	4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-08-24 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Aug-05-24 08:00AM	4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board (GlobeNewswire) -5.97%
Jul-17-24 05:00AM	4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity (GlobeNewswire) -31.96%
Jul-12-24 09:40AM	4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last? (Zacks) +5.54%
Jul-08-24 05:52PM	4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock? (Insider Monkey) +5.58%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 08:00AM	4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy (GlobeNewswire)
Jun-18-24 08:00AM	4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast (GlobeNewswire)
Jun-08-24 04:30PM	4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-06-24 07:30AM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference (GlobeNewswire) -17.27%
Jun-04-24 08:00AM	4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-03-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-30-24 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47 European Cystic Fibrosis Conference (GlobeNewswire)

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Executive ChairmanDr. John F. Milligan Ph.D.

Co-FounderDr. David H. Kirn M.D.

CFO and Principal Financial & Accounting OfficerMr. Kristian Humer M.B.A.

Chief Technical AdvisorDr. Fariborz Kamal Ph.D.

Co-Founder & Chief of StaffMs. Theresa Janke

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCOTT BIZILY	Officer	Jun 30 '26	Proposed Sale	12.88	6,566	84,570		Jun 30 04:38 PM
Bizily Scott	Chief Legal Officer	Jun 23 '26	Option Exercise	4.14	9,810	40,613	18,427	Jun 25 04:38 PM
Bizily Scott	Chief Legal Officer	Jun 23 '26	Sale	12.00	9,810	117,720	8,617	Jun 25 04:38 PM
SCOTT BIZILY	Officer	Jun 23 '26	Proposed Sale	10.42	9,810	102,220		Jun 23 04:29 PM
Kirn David	See Remarks	Jun 22 '26	Sale	10.47	114,746	1,200,851	942,485	Jun 23 04:19 PM
David Kirn	Officer	Jun 22 '26	Proposed Sale	10.42	114,746	1,195,653		Jun 22 05:58 PM
Kirn David	See Remarks	Jun 01 '26	Sale	10.02	1,922	19,258	1,057,231	Jun 02 04:48 PM
David Kirn	Officer	Jun 01 '26	Proposed Sale	9.71	1,922	18,663		Jun 01 05:40 PM
Gupta Ashoo	VP, Finance and Controller	Mar 20 '26	Sale	8.61	390	3,358	46,914	Mar 24 06:30 PM
Gupta Ashoo	VP, Finance and Controller	Dec 20 '25	Sale	8.68	389	3,377	46,218	Dec 23 09:05 PM
Bizily Scott	Chief Legal Officer	Dec 16 '25	Option Exercise	4.14	1,635	6,769	5,229	Dec 19 04:10 PM
Bizily Scott	Chief Legal Officer	Dec 16 '25	Sale	10.90	1,635	17,822	3,594	Dec 19 04:10 PM
THEUER CHARLES	Director	Dec 12 '25	Option Exercise	1.14	9,333	10,640	41,684	Dec 16 04:35 PM
SCOTT BIZILY	Officer	Dec 16 '25	Proposed Sale	10.95	1,635	17,903		Dec 16 04:33 PM
Bizily Scott	Chief Legal Officer	Nov 17 '25	Option Exercise	4.14	1,635	6,769	5,229	Nov 19 09:53 PM
Bizily Scott	Chief Legal Officer	Nov 17 '25	Sale	10.59	1,635	17,315	3,594	Nov 19 09:53 PM
SCOTT BIZILY	Officer	Nov 17 '25	Proposed Sale	10.79	1,635	17,642		Nov 17 04:33 PM
Bizily Scott	Chief Legal Officer	Oct 24 '25	Option Exercise	6.49	1,084	7,035	6,272	Oct 27 06:19 PM
Bizily Scott	Chief Legal Officer	Oct 24 '25	Sale	12.00	2,678	32,136	3,594	Oct 27 06:19 PM
SCOTT BIZILY	Officer	Oct 24 '25	Proposed Sale	10.00	1,816	18,160		Oct 24 04:26 PM
Bizily Scott	Chief Legal Officer	Oct 16 '25	Option Exercise	4.14	1,635	6,769	6,823	Oct 20 07:51 PM
Bizily Scott	Chief Legal Officer	Oct 16 '25	Sale	10.17	1,635	16,628	5,188	Oct 20 07:51 PM
Bizily Scott	Chief Legal Officer	Oct 09 '25	Sale	10.00	2,408	24,080	5,188	Oct 14 04:04 PM
Bizily Scott	Chief Legal Officer	Sep 23 '25	Sale	8.00	2,407	19,256	7,596	Sep 26 09:50 PM
SCOTT BIZILY	Officer	Sep 23 '25	Proposed Sale	7.40	7,312	54,109		Sep 23 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

4D Molecular Therapeutics Inc

Upgrade your Finviz experience